A Phase 1 study of KBP-5209 in patients with advanced solid tumors
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to find the highest dose of study drug (KBP-5209) that can be given safely in humans, and to determine the immediate and long-term side effects of treatment with KBP-5209 when it is taken orally every day on a continuous basis.
Description
The purpose of this study is to establish a safe dose range based on side effects and to get an idea of how well the drug might work in treating cancer.
Details
| Condition | solid tumor |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX4970 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.